HIV Protease: Viral Lifecycle Role and Protease Inhibitor Therapeutics

HIV-1 protease (PR) is a 99-amino-acid aspartyl protease essential for viral maturation. It cleaves the Gag and Gag-Pol polyproteins into functional structural (MA, CA, NC, p6) and enzymatic (RT, IN, PR) proteins.

Mechanism

  • Dimeric enzyme; active site Asp25-Thr26-Gly27.
  • Cleaves >10 specific sites in polyproteins during/after budding.
  • Without PR: immature, non-infectious virions.

Protease Inhibitors (PIs) — Drug Class Evolution

GenerationAgentsKey Features
1stSaquinavir, Indinavir, Ritonavir, NelfinavirHigh pill burden, toxicity (lipodystrophy, GI), moderate resistance barrier
2ndLopinavir/r, Atazanavir/r, Fosamprenavir/rBoosted with ritonavir; better PK, once-daily options
3rd / BoostedDarunavir/r, Darunavir/cobicistat, Atazanavir/cobiHigh genetic barrier, broad resistance coverage, preferred for treatment-experienced

Clinical Impact

  • PIs + 2 NRTIs = standard HAART backbone (1996–).
  • Transformed HIV from fatal to chronic manageable condition.
  • Resistance: Major mutations (D30N, V82A, I84V, L90M) reduce susceptibility; darunavir retains activity against many PI-resistant strains.

Current Guidelines

Integrase inhibitors (bictegravir, dolutegravir) now preferred first-line; PIs reserved for resistance, pregnancy (ATV/r, DRV/r), or specific scenarios.

HIV & AIDS - Related Articles